دورة المؤشرنت للتحليل الفني
50 دينار كويتي
alth,,,,,,,,,,,,,, واليوم الحاسم
- بادئ الموضوع stockolic
- تاريخ البدء
stockolic
عضو نشط
- التسجيل
- 18 مايو 2009
- المشاركات
- 466
السهم سيكون مشروع مضاربه قويه بكره بعد هذا الاعلان
Allos Therapeutics, Inc. Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN (pralatrexate) For The Treatment of Patients
6:09pm EDT
Allos Therapeutics, Inc. announced that the U.S. Food and Drug Administration`s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PTCL comprises a biologically diverse group of aggressive blood cancers that has a worse prognosis than most other types of lymphoma, including B-cell lymphoma. If approved, FOLOTYN would be the first drug approved by the FDA for the treatment of relapsed or refractory PTCL
Allos Therapeutics, Inc. Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN (pralatrexate) For The Treatment of Patients
6:09pm EDT
Allos Therapeutics, Inc. announced that the U.S. Food and Drug Administration`s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PTCL comprises a biologically diverse group of aggressive blood cancers that has a worse prognosis than most other types of lymphoma, including B-cell lymphoma. If approved, FOLOTYN would be the first drug approved by the FDA for the treatment of relapsed or refractory PTCL
دورة المؤشرنت للتحليل الفني
50 دينار كويتي